Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
NAUT Stock Chart & Stats
$2.62
$0.07(3.48%)
At close: 4:00 PM EST
$2.62
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.62 - $3.08
Previous CloseN/A
Volume21.91K
Average Volume (3M)394.63K
Market Cap
$305.02M
Enterprise Value$348.55M
Total Cash (Recent Filing)$103.41M
Total Debt (Recent Filing)$30.02M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
May 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding126,564,476
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.91
Enterprise Value/Ebitda-6.63
Forecast
1Y Price Target
$4.00Price Target Upside52.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Proprietary Voyager PlatformThe Voyager instrument provides a durable technical moat: a novel benchtop system designed to map billions of intact proteins and proteoforms, giving Nautilus a tangible product ahead of broad GA. This structural IP and tangible platform reduce scientific execution risk and underpin future instrument+consumable recurring revenue once commercialized.
External Scientific Validation & CollaborationsIndependent biological validation from respected research partners demonstrates differentiated assay capability and scientific credibility. Such third‑party validation lowers adoption barriers, supports downstream partnerships and publications, and materially increases the odds that Voyager and its assays earn trust among core research and pharma customers over the medium term.
Improved Cash Position And Expense DisciplineReduced operating spend and a cash balance providing runway through 2027 materially lower immediate financing pressure. Demonstrated cost discipline and improved burn rate give management time to execute Early Access, instrument preorders, and initial installs, increasing odds the company reaches commercial inflection without immediate dilution.
Bears Say
Zero Reported Revenue; Persistent LossesNautilus remains pre‑revenue with multi‑year net losses, meaning the business model and recurring consumables economics are unproven. Continued operating losses erode equity and create structural financing needs; without demonstrated revenue, commercial scale and margin sustainability remain speculative over the next several quarters.
Planned 2026 Spending Step‑up Increases Funding RiskManagement expects a meaningful increase in 2026 operating expense and cash burn versus 2025, which tightens the cash runway profile and raises the probability of additional external funding. Higher near‑term investment is strategic but increases dilution and execution risk if commercial traction lags assumptions.
No Sales Organization; Commercialization Execution RiskAbsent an established sales force and commercialization infrastructure, converting Early Access interest into instrument orders and recurring consumables revenue will be slow and execution‑sensitive. Building commercial capability is time‑consuming and raises the risk that planned 2026‑2027 revenue ramps slip or underdeliver versus milestones.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $3.08 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $305.02M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is May 05, 2026 which is in 60 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Feb 26, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.03.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.15.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 126,564,476 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -16.263%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (52.67% Upside)
$4.00 (52.67% Upside)
Insider Transactions
Bought Shares
Worth $65.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.0%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-32.00%
Trailing 12-Months
Asset Growth
-21.84%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful technical progress, strong external validation, the successful public debut of the Voyager instrument, the early launch of an Early Access Program (Tau assay) and disciplined expense reductions that improved cash burn and extended runway through 2027. Offsetting these positives are limited near-term revenue (modest 2026 services revenue targeted at ~$0.5M), no current sales organization, and a planned increase in 2026 operating expenses and cash burn as the company invests to advance commercialization. On balance, the developments point to a company transitioning from development to early customer engagement with tangible validation and a clear commercialization timeline, though revenue and commercial execution risks remain in the near term.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(52.67% Upside)
Technical Analysis
Ownership Overview
35.50% Insiders
2.55% Mutual Funds
40.96% Other Institutional Investors
19.09% Public Companies and
Individual Investors